Abstract:Philadelphia chromosomes 9 and 22 encode BCR and ABL1 genes, respectively. Translocation mutation of two chromosomes generates the fused BCR-ABL1 gene. The resulting fused gene encodes the chimeric BCR-ABL oncoprotein with constitutively enhanced and dysregulated tyrosine activity to disturb different cell signaling. Ras/MAPK is a significant pathway in mediating cell proliferation and its hyperactivation is responsible for malignant transformation in cancer. Autophosphorylation Y177 (pY177) of BCR protein stimulates the direct binding of an adaptor protein GRB2, which is involved in Ras/MAPK pathway. In BCR-ABL-associated Ras/MAPK signaling pathway, BCR-ABL can target GRB2 through the interaction of its pY motif with GRB2 SH2 domain, followed by SOS recruitment to the plasma membrane by GRB2. The resulting BCR-ABL/GRB2/SOS assembly stimulates the transformation of inactive GDP-bound form of Ras to the active GTP-bound state, which causes the constitutive activation of the downstream components of Raf/MEK/ERK. Despite a number of biophysical experiments have showed that BCR-ABL is able to recruit GRB2, the molecular-level understanding of how the two proteins interact with each other remains to be elucidated. In this work, we used molecular modeling and molecular dynamics (MD) simulations to study the structural basis for the binding between BCR-ABL and GRB2 SH2 domain to explain CML oncogenesis at the atomic level. Different pY/Y-peptide-SH2 complex models have been constructed and their binding specificity and affinity were compared. Simulation results showed that phosphorylated BCR (pBCR) specifically binds to GRB2 SH2 domain through its five-residue 176FpYVNV180 motif. GRB2 SH2 domain contains two binding pockets: the pY-binding pocket for the phosphate recognition and the specificity pocket for the selection of Asn. pY177 triggers the binding through the interaction in pY-binding pocket. The interaction in specificity pocket determines the binding specificity, which is regulated by N179 in pBCR and W121 in EF loop of GRB2 SH2 domain. In addition, the interaction in the specificity pocket experiences conformation selection for both the bound motif in pBCR and GRB2 SH2 domain; the binding motif adopts type I β-turn conformation and the specificity pocket of GRB2 SH2 domain displays the closed conformation. This specific binding mode between pBCR and GRB2 SH2 domain is similar with that between phosphorylated EGFR (pEGFR) and GRB2 SH2 domain. Residues adjacent to the pY and Arg residue at the +2 position C-terminal to pY in the binding motifs influence the binding affinity of a pY-peptide to GRB2 SH2 domain, explaining why pBCR shows stronger affinity to GRB2 SH2 domain than pEGFR. Our study supports the BCR-ABL oncoprotein recruitment of GRB2 for the induction of CML through Ras/MAPK pathway and provides deeply understanding of the specific interaction of the pY motif with GRB2 SH2 domain at atomic level. Citation Format: Yonglan Liu, Hyunbum Jang, Mingzhen Zhang, Chung-Jung Tsai, Ryan Maloney, Ruth Nussinov. The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2919.

Higher-order interactions of Bcr-Abl can broaden chronic myeloid leukemia (CML) drug repertoire

Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

Inhibition of Abl Kinases by Intramolecular and Intermolecular Interactions: A Lesson from Structure Studies and CML Therapy

Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation Via Distinct Structural Degrons.

Integrating amino acids into Bcr-Abl inhibitors: design, synthesis, biological evaluation, and in silico studies

Design, Synthesis, and Biological Evaluation of Trizole-Based Heteroaromatic Derivatives As Bcr-Abl Kinase Inhibitors.

Abstract 2919: The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia

E3 Ligase C-Cbl Mediates Ubiquitination-Proteasomal Degradation Of Bcr-Abl And Therapeutic Effects Against Bcr-Abl Leukemia

Structure-guided drug design targeting Abl kinase: how structure and regulation can assist in designing new drugs

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Cloning, Expression, Purification and Functional Characterization of the Oligomerization Domain of Bcr–Abl Oncoprotein Fused to the Cytoplasmic Transduction Peptide

[Role and Mechanism of the Interaction of BCR-ABL with E3 Ligase C-Cbl in Targeting Therapy of Chronic Myelogenous Leukemia].

The Coiled-Coil Domain And Tyr177 Of Bcr Are Required To Induce A Murine Chronic Myelogenous Leukemia-Like Disease By Bcr/Abl

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia

Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1

Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

The NH2-Terminal Coiled-Coil Domain and Tyrosine 177 Play Important Roles in Induction of a Myeloproliferative Disease in Mice by Bcr-Abl